Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has 3 years of Other Non-Current Liabilities data on file, last reported at $9000.0 in Q1 2022.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $9000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $9000.0 (changed N/A YoY) and the FY2021 annual result came in at $17000.0, down 90.34% from the prior year.
• Other Non-Current Liabilities fell to $9000.0 in Q1 2022 per CRBU's latest filing, from $17000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $176000.0 in Q4 2020 and bottomed at $9000.0 in Q1 2022.
• The 3-year median for Other Non-Current Liabilities is $153000.0 (2021), against an average of $103600.0.
• Peak annual rise in Other Non-Current Liabilities reached 90.34% in 2021, while the deepest fall reached 90.34% in 2021.
• Tracing CRBU's Other Non-Current Liabilities over 3 years: stood at $176000.0 in 2020, then slumped by 90.34% to $17000.0 in 2021, then plunged by 47.06% to $9000.0 in 2022.
• Per Business Quant, the three latest CRBU Other Non-Current Liabilities figures stand at $9000.0 (Q1 2022), $17000.0 (Q4 2021), and $153000.0 (Q3 2021).

Peer Comparison